|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, it was implied that miR-150 could inhibit colorectal cancer progression and serve as a tumor suppressor via inactivating β-catenin pathway.
|
31731194 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings demonstrate that circLMTK2 functions as a tumour promoter in GC through the miR-150-5p/c-Myc axis and could thus be a prognostic predictor and therapeutic target for GC.
|
31722712 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of tumor xenograft further confirmed the role of miR-150 in Burkitt lymphoma.
|
30422313 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-150 Suppresses Tumor Growth in Melanoma Through Downregulation of MYB.
|
29690954 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Circulating miRNAs including miR-150-5p are associated with colorectal cancer progression, and the putative targets of miR-150-5p include tumor suppressor gene, TP53.
|
31043658 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that miR-150 binding on specific recognition sites in 3' UTR of tumor suppressor gene SRCIN1 present a potential therapeutic target for NSCLC.
|
28891208 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The in vivo result indicated that MSCs-Exo can penetrate the tumor site and are suitable nanovehicles to deliver the inhibitory oligonucleotides into the tumor tissues to downregulate the expression levels of miR-142-3p and miR-150.
|
30538455 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-150 functions as a tumor suppressor in malignancies of the lymphocyte lineage and its expression is significantly reduced in these cells.
|
30269036 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on these results, we conclude that miR-150-5p may function as a tumor suppressor in CRC, and miR-150-5p/VEGFA axis may be a potential therapeutic target candidate in CRC treatment.
|
30476901 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our results highlight a novel activity for CDK3 in myoblast cell proliferation and confirm CDK3 as a key target that further enhances the tumor suppressor function proposed for miR-150.
|
28108217 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The miR-34a and miR-150 levels in the tumor tissues were significantly lower than in pancreatic tissues with benign lesions.
|
27458977 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results show that two known oncomiRs, miR-155 and -92a were upregulated and the tumour suppressor miR-150 was downregulated in the PCs.
|
28407516 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, our results uncover a novel mechanistic understanding of miR‑150-mediated tumor suppression in NPC, which will facilitate the development of effective cancer therapies against nasopharyngeal carcinoma.
|
28350089 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
|
27935859 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, miR-150 was found to be a tumor suppressor, and the suppression of miR-150 resulted in elevation in the levels of ROCK1.
|
28454380 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Esophageal squamous cell carcinoma (ESCC) patients from our hospital were recruited to collect tumor and adjacent tissues for miR-150 and Gli1 expression.
|
29081413 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low levels of miR-150 were significantly associated with worse clinicopathological characteristics and a poor prognosis for patients with HCC. miR-150 overexpression inhibited cell proliferation, migration and invasion in vitro and tumor growth and metastasis in vivo.
|
26871477 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
|
27447965 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these findings suggest that miR-150 functions as a tumor suppressor in OS partially by targeting IGF2BP1.
|
26561465 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our study demonstrates that miR-150 functions as a tumor suppressor through multiple mechanisms in human leukemia and provides a rationale for utilizing miR-150 as a novel therapeutic agent for leukemia treatment.
|
27899822 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The regulatory microRNA miR-150 is involved in the development of hemopathies and is downregulated in T-lymphomas, such as anaplastic large-cell lymphoma (ALCL) tumors.
|
26258416 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, miR-15b-5p, miR-126-3p, miR-93-5p, and miR-150-5p were common to tumor/WBCs, while miR-720/3007a, miR-205, miR-200c-3p and miR-29b-3p common to tumor/urine.
|
26576778 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, a high level of serum miR-150 was associated with tumor burden markers and some markers of poor prognosis.
|
25584781 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When immunodeficient mice were injected with miR-150(-/-) NK cells, there was a significant reduction in tumor growth and metastasis of B16F10 melanoma.
|
24698324 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report that miR-150 is a key regulator in the tumourigenesis and progression of colorectal cancer, by acting as a tumour suppressor targeting c-Myb.
|
25230975 |
2014 |